

Hallal David  
Form 4  
November 05, 2010

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2010  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Hallal David

2. Issuer Name and Ticker or Trading Symbol  
ALEXION PHARMACEUTICALS INC [ALXN]

5. Relationship of Reporting Person(s) to Issuer  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
SVP Commercial Ops, Americas

(Last) (First) (Middle)

C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE

3. Date of Earliest Transaction (Month/Day/Year)  
11/03/2010

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

CHESHIRE, CT 06410

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)           | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|---|--------------------------------------|--|--------------------------------|---|---|--|--|
|   |                                      |  | Code                           | V   | Amount or (D) Price   |  |  |
| Common Stock, par value \$.0001 per share | 11/03/2010                           |  | S                              |   | 1,619 D \$ 70.43  | 4,770  | D  |
| Common Stock, par value \$.0001 per share | 11/03/2010                           |  | S                              |   | 1,000 D \$ 70.42  | 3,770  | D  |

Edgar Filing: Hallal David - Form 4

|   |            |   |        |   |                           |        |   |
|---|------------|---|--------|---|---------------------------|--------|---|
| Common<br>Stock, par<br>value<br>\$.0001 per<br>share | 11/04/2010 | M | 20,000 | A | \$<br>16.32               | 23,770 | D |
| Common<br>Stock, par<br>value .0001<br>per share      | 11/04/2010 | S | 20,000 | D | \$<br>70.29<br><u>(1)</u> | 3,770  | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount of<br>Underlying Securities<br>(Instr. 3 and 4) |        |                                     |
|---|--|---|---|--------------------------------------|--|--|---|--------|-------------------------------------|
|   |  |   |   | Code                                 | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date  | Title  | Amount<br>or<br>Number<br>of Shares |
| Option to<br>Purchase<br>Common<br>Stock            | \$ 16.32   | 11/04/2010                              |   | S                                    | 20,000   | 09/16/2006 06/19/2016  | Common<br>Stock, par<br>value<br>\$.0001<br>per share               | 20,000 |                                     |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships   |
|---|---|
| Hallal David<br>C/O ALEXION PHARMACEUTICALS, INC<br>352 KNOTTER DRIVE<br>CHESHIRE, CT 06410 | Director 10% Owner Officer<br>SVP Commercial Ops, Americas<br>Other |

## Signatures

/s/ David Hallal

11/05/2010

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$72.13 - \$72.69. The price reported in this (1) column reflects the weighted average sales price. Upon request, the reporting person shall provide to the SEC staff full information regarding the number of shares sold at each price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.